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Abstract
Asthma is a chronic inflammatory heterogeneous disease of the lower respiratory tract characterised by the occurrence of 
bronchial hyper-responsiveness and paroxysmal, changeable bronchial obstruction. Transforming growth factor-beta (TGF-b) is 
one of the cytokines involved in mediating airway inflammation and remodelling. The level of TGF-b1 gene expression correlates 
with severity of symptoms. Alterations in the main SMAD signal transmission, overexpression of TGF-b genes and changes 
in the transcriptome cause excessive secretion of TGF-b and its increased expression in target cells, which clinically induces 
a moderate-severe or severe course of asthma as well as an earlier and faster disease progression. Knowledge of these processes 
allows clinicians to assess immune responses in patients, which affects adequate disease control and prevention of remodelling.
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Introduction
in the context of understanding the heteroge-
neous pathogenesis and development of asthma, 
a special attention of researchers has been focused 
on the transforming growth factor beta (TGF-b). 
Although nowadays five types of isoforms of this 
factor have been identified, there are only three 
isoforms found in the human body (TGF-b1, 
TGF-b2, TGF-b3), each one coded by separate 
genes. Depending on a type of tissue, a proper 
isoform and its concentration, they affect the 
processes of synthesis, proliferation, differenti-
ation, and apoptosis of the extracellular matrix 
components and the maintenance of appropriate 
homeostasis of the human organism [1]. 
TGF-b superfamily
TGF-b superfamily is an evolutionarily highly 
conserved superfamily of proteins, already pres-
ent in Drosophila sp., in which the expression of 
genes associated with TGF-b influences the for-
mation of organ structures in early embryogenesis 
and communication between particular tissues in 
their later development. The superfamily of TGF-b 
is divided into three subfamilies according to the 
similarity of sequences and specific signalling path-
ways, which activate the first subfamily including 
the transforming growth factor beta (TGF-b) and 
activins. The second subfamily is represented by 
the secretory protein synthesized in cells of the 
nodal growth differentiation factor (NODAL) and 
the glial cell derived neurotrophic factor (GDNF). 
The third one comprises bone morphogenetic pro-
teins (BMPs), growth differentiation factors (GDFs) 
and anti-mullerian hormone (AMH) [2, 3].
Molecular Structure
A dimeric molecule is an active form of 
TGF-b whose monomers consist of a few b strands 
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spatially arranged by three disulphide bonds in 
a cysteine knot structure. Hydrophobic bonds and 
disulphide bridges stabilize a dimeric molecule 
and its arrangement affects subsequent formation 
of complexes with one of two types of receptors 
for TGF-b [4].
Mapping and promoters
 There are three various isoforms of the trans-
forming growth factor in the human body, which 
are localized on chromosomes TGF-b1-19q13, 
TGF-b2-1q41 and TGF-b3-14q24, respectively, 
whose regulation occurs at the transcriptional 
level [5]. A promoter for TGF-b2 and TGF-b3 iso-
forms possesses in its structure a classical TATAA 
box domain and a CRE-ATF terminal region that 
are subject to hormonal control [6, 7]. However, 
the promoter for TGF-b1 does not contain the 
TATAA box, but has a sequence of regulatory sites 
capable of activation due to proto−oncogenes, 
such as c-jun, c-fos or egr-1, and also oncogenes 
abl, fos, jun, ras and src [8]. This enables TGF-b 
promoter’s activity to be inhibited by tumour 
suppressor genes and the products of expression 
of retinoblastoma or Wilms’ tumour genes. 
Each gene of particular isoform codes for 
a pre-pro-peptide, which undergoes division into 
two peptides by furin-like protease in the Golgi 
apparatus. A 24kDa-homodimer of the mature 
TGF-b is non-covalently bound to 80kDa-laten-
cy-associated peptide (LAP) forming a small 
latent complex (latent TGFb-binding protein LT-
GF-b) [9]. The essential role of this complex is to 
transport TGF-b to the extracellular matrix. TGF-b 
included in the latent complex lacks the ability to 
bind to its receptors, which is affected by various 
factors, such as fluctuations of temperature and 
pH, ionizing radiation, and thrombospondins or 
plasmins. The junction of TGF-b, pro-peptide 




The best recognized isoform is a highly 
pleiotropic cytokine of TGF-b1 located on chro-
mosome 19q13, and expressed in endothelial, 
hematopoietic and connective tissue cells. It 
is synthesized in the human body by activated 
T and B lymphocytes, macrophages, platelets and 
neutrophils [11]. TGF-b1 activity has so far been 
regarded as anti-inflammatory, it has been stated 
that its activity may be also pro-inflammatory 
[12, 13]. TGF-b1 has immunosuppressive effects 
on T and B lymphocytes, and NK cells as well 
as inhibits expression of MHC class II antigens 
[14]. A deficiency or total lack of this cytokine may 
predispose people to more frequent manifestation 
of autoaggressive diseases such as systemic lupus 
or systemic sclerosis [15, 16]. TGF-b1 also plays 
a role in the pathogenesis of vascular inflammatory 
states in atheromatosis and vascular changes in the 
Alzheimer disease, articular inflammations, and 
hepatic cirrhosis associated with the HCV infec-
tion or progression of diabetic nephropathy [17].
A special role is ascribed to the TGF-b1 cy-
tokine in the pathogenesis and development of 
allergic diseases, particularly bronchial asthma. 
This is connected with the ability to induce che-
moattractive activity of fibroblasts, stimulate their 
proliferation, and increase the synthesis of fibro-
blasts, fibronectin, proteoglycans and type I and 
III collagen, as well as to inhibit gene expression 
of collagenases and matrix metalloproteinases. 
The cytokine level significantly increases in the 
course of bronchial asthma [18, 19]. Moreover, 
the release of TGF-b1 by eosinophils in the 
submucosa of bronchial airways is favoured by 
a series of environmental factors such as com-
mon inhaled allergens or tobacco smoke. Hence, 
a closer examination is required of the correla-
tions between the level of asthma intensity and 
development and the occurrence of inhaled aller-
gy or long-term smoking in patients [20]. Experi-
mental studies performed in various international 
research centres revealed an increased TGF-b1 
gene expression, with simultaneously reduced 
eosinophil migration to the inflammatory focus 
in the airways of tobacco smokers [21]. The de-
gree of inflammatory reaction intensity depends 
on individual sensitivity as well as on genetic 
components. Genes directly associated with the 
onset of the pathological process are thought to 
be genes involved in the regulation of the IgE 
level and those affecting individual bronchial 
hyper−reactivity. Genes regulating the develop-
ment and maintenance of chronic inflammation, 
airway remodelling and the response to treatment 
with particular consideration to glucocorticoste-
roids are responsible for severity of the disease 
[22]. One of the genes whose expression level 
correlates with a degree of severity of asthma 
symptoms is the TGF-b1 gene [23, 24]. In control 
group patients with mild, moderate to severe, and 
severe course of asthma, four polymorphic forms 
of the promoter region (C-509T, 72insC, T869C 
and G915C) were observed [25]. A significant role 
was played by C-509T, in which a single nucleo-
tide polymorphism (C/T at position 509) caused 
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the formation of YY1-binding site — a probable 
new site for binding transcription factors. In 
practice, it is manifested by the elevated serum 
TGF-b1 cytokine and IgE levels [26]. Patients 
homozygous for 509T allele usually produced 
a haplotype 1, occurring in the majority of groups 
with moderate to severe and severe symptoms, as 
compared to the group of controls and patients 
with mild asthma. It has been proven that people 
with a haplotype 1 were also homozygous for 72C, 
869C, and 915C variants [25, 27]. The study of 
a haplotype variant as a risk factor for disease 
severity may help in prognosing asthma develop-
ment in a particular patient. Moreover, the pres-
ence of the four single nucleotide polymorphisms 
(SNPs-509T, 72C, 869C and 915C) correlates with 
an increased predisposition to atopy [28].
TGF-b2
TGF-b2 isoform is predominantly produced 
in the nerve and epithelial cells. TGF-b2 has been 
mapped to chromosome 1q41. Its expression is 
seen at the level of embryogenesis in such tissues 
as the epithelium of bronchi, auditory meatus, 
lenses, and retina or mesenchyme, as well as in 
precartilaginous blastema and a later growth zone 
of long bone, which indicates the effect of TGF-b2 
on skeletal formation [29, 30]. Its overexpression 
is especially visible in diseases with matrix fibro-
sis such as bronchial asthma, optic nerve hypo-
plasia, or primary open−angle glaucoma [31, 32]. 
TGF-b2 is also subject to a strong expression in 
various cancer cell lines, which is associated with 
the promotion of cancer cell survival through 
the activation of a nuclear factor kappa B (NF-
kB). Its effect on the development of ovarian 
and prostate cancer or glioblastoma multiforme 
has been evidenced, and its ability to degrade 
the extracellular matrix favours migration and 
invasion of tumour cells. TGF-b2 is regarded as 
an important cytokine in the process of embry-
onic morphogenesis, and a reduced TGF-b2 gene 
expression leads to developmental disorders con-
cerning mainly facial skeleton, organs of vision 
and hearing, vertebral column or cardiovascular 
system [33]. TGF-b2 overexpression is more often 
observed in the case of congenital and acquired 
structural defects as well as in cardiac valve 
fibrosis, sporadically in Fallot’s tetralogy, while 
loss of heterozygosity (LOH) in the TGF-b2 gene 
is associated with a more frequent occurrence 
of symptomatic aortic aneurysm originated by 
histopathological changes in a form of fragmen-
tation of elastin fibres and excessive collagen and 
proteoglycan deposition, also observed in the 
pathogenesis of bronchial asthma [34]. Multifold 
higher levels of this cytokine were detected in 
respiratory tract biopsies obtained from asth-
ma patients as compared to healthy subjects. 
Moreover, in the biopsy material from asthma 
patients, the TGF-b2 level was found to be higher 
than that of TGF-b1. The TGF-b2 involvement in 
airway remodelling correlates with an increase 
in mucin expression in bronchial epithelial cells 
[35]. There are some hypotheses that interleukin 
13 (IL-13) produced in excessive amount by Th2 
lymphocytes, eosinophils and NK cells may in-
crease the TGF-b2 secretion through epithelial 
cells [36, 37]. A significant increase in TGF-b2 
positive eosinophils and macrophages was also 
observed in immunohistochemical staining of the 
bronchial epithelium from patients with moderate 
and severe asthma after the allergen challenge, 
whereas bronchoalveolar lavage (BAL) revealed 
an increase in the level of both TGF-b isoforms in 
the bronchial epithelium of those patients [38].
TGF-b3
The third TGF-b isoform (TGF-b3), whose 
gene is located on chromosome 14q24, undergoes 
expression especially in mesenchymal tissues, 
which can affect proliferation and differentiation 
of primary cells of internal organs, bronchial 
epithelium, aortic intima endothelium, as well 
as perichondrium and chondroblasts involved 
in the formation of primary embryonic skel-
eton [39]. It has been proven that lack of this 
isoform can lead to developmental defects of 
palate and lungs. TGF-b3 with TGF-b1 induces 
the expression of fibroblast growth factors, and 
TGF-b3 alone exerts a great impact on fibroblast 
proliferation [14].
Cytokines from the TGF-b family participate 
in the maturation and secretion of pituitary gland 
secretory cells. TGF-b3 released by lactotrophic 
cells in adequate amounts stimulates the function 
of folliculotrophic cells that reversibly stimulate 
lactotrophic cells, which is regarded as one of 
the mechanisms promoting TGF-b3 involvement 
in developing prolactinoma. TGF-b3 and TGF-b2 
isoforms occur in glial and microglial cells, as 
well as in astrocytes and oligodendrocytes [40]. 
Moreover, TGF-b3 is an important regulator 
of neuron differentiation, a neurite stimula-
tor and cofactor of neurotrophic factors, e.g. 
a glial cell-derived neurotrophic factor (GDNF), 
neurotrophins (NT), ciliary neurotrophic factor 
(CNTF), or fibroblast growth factor 2 (FGF 2), and 
is extremely promising for use in regeneration of 
neurons in culture [41] (Table 1).
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Table 1.  Localization of the expression of mRNA coding 
TGF-b 1−3 isoforms
Localization of the expres-








Hematopoietic tissue + − −
Epithelia








   − salivary glands + + −
   − suprabasal keratinocytes − + −
   − otic epithelium − + −
   − lens − + −
   − retina − + −
   − olfactory epithelium − + −
Immature epidermis − − −
Cartilage and bone
   − precartilaginous blastema − + +
   − growth zone of long bone − + −
   − perichondria − − +
   − osteoblasts + − −
   − osteoclasts + − −
Cardiovascular tissue
   − pre-valvular endothelium + − −
   − myocardium + − −
   − aortic intima − + −
Endocrine system
   − thyroid gland + − −
   − parathyroid glands + − −
   − thymus + − −
Neuronal tissue
   − ventral spinal cord − + −
Mesothelium − − +
Mesenchyme − + +
TGF-bs are pleiotrophic compounds pro-
duced by the majority of fibroblastic or epithelial 
cells. They stimulate proliferation of chondro-
blasts, osteoblasts, and neuronal tissue cells. 
TGF-bs are growth inhibitors for epidermal, 
endothelial, hematopoietic cells and for some 
types of mesenchymatic cells [42]. Due to multidi-
rectional activity, they must be subject to precise 
regulation — loss of control over their activity at 
each stage of the individual development may 
lead to induction of various diseases including 
neoplasms. They combine properties of growth 
factors and cytokines, for which they use specific 
receptors that transmit signals, two of them with 
serine-threonine kinase activity (TGF-b RI and 




Involvement of two types of membrane re-
ceptors and mediating proteins from the SMAD 
family is necessary for the transduction of TGF-b 
into the inside of the cell. The name of this family 
is derived from two homologous Sma proteins 
occurring in Caenorhabditis elegans and Mad 
present in Drosophila melanogaster [43].
The SMAD protein family is divided into 
three groups: proteins activated by the 
R-SMAD receptor to which SMAD 1,2,3,5,8 
belong; Co-SMAD, the protein co-mediating 
Smad4; and the third group, the inhibitory I-SMAD 
proteins with representatives SMAD 6,7 [44].
R-SMAD proteins are responsible for trans-
mitting a signal into the cell nucleus. Structurally, 
they consist of MH domains (homology with the 
Drosophila protein Mad) separated from each 
other by a binding element. The N-terminal do-
main is responsible for binding to DNA, while the 
C-terminal domain interacts with other proteins. 
Inactive forms of R-SMAD can be found in the 
cell cytoplasm [45]. 
The second subtype of SMAD proteins is 
a mediating protein Co-SMAD , whose the only 
representative is SMAD 4. It participates in the 
formation of a complex with phosphorylated 
R-SMAD proteins, enabling them to penetrate into 
the cell nucleus from the cytoplasm.
There is the third type of proteins, inhibitory 
(I-SMAD) SMAD 6,7, in the cell nucleus. Their 
structure differs from the first group of the protein 
superfamily: they consist only of the C-terminal 
domain, without the N-terminal domain [44].
TGF-b receptors
 Three types of membrane receptors are found 
in the cell membrane: type I receptor (TGFR-II), 
type II (TGFR-II) and type III (TGFR-III).
A type I receptor (TGFR-II) (called a type Alk 
receptor) is a glycoprotein with a molecular mass 
of 53kDa. There are seven subgroups from Alk1 
to Alk7. TGF-b mainly acts through three types 
of receptors: Alk1 — occurring in endothelium; 
Alk2 — in cells of the cardiovascular system 
and in the ventral portion of mesoderm during 
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Figure 1. Regulation of gene transcription through SMAD signaling pathway
embryogenesis [46]; and the most important 
Alk7 — located in fibroblasts, skeletal progenitor 
cells, osteoblasts, chondroblasts and perichondri-
um [47]. The remaining subtypes Alk 3,4,6 are 
activated particularly by bone morphogenetic 
proteins (BMP) [48].
A type I receptor consists of a domain with 
a protein serine/threonine kinase activity in the 
transmembrane region and the ligand-binding 
domain. The glycine/serine-rich domain (GS) 
(amino acid sequence SGSGSG) occurs outside 
the membrane [49].
A TGFR-II receptor is a glycoprotein with 
a molecular mass of 85-110 kDa made up of the 
N-terminal ligand-binding domain, transmem-
brane region and C-terminal domain with a pro-
tein serine/threonine kinase activity [50]. 
TGF-b exhibits a high affinity for the type II 
receptor and lack of affinity for the type I recep-
tor. Ligands initially bind to TGFR-II. A large li-
gand-receptor complex is formed, which consists 
of a TGF-b protein dimer and two molecules of the 
TGFR-II receptor as well as of two TGFR-II mole-
cules. This binding enables serine and threonine 
residues to be phosphorylated in the GS domain 
of the TGFR-II receptor through type II, which 
causes their activation [51].
Signalling pathway 
Secondary signalling molecules, i.e. R-SMAD 
proteins (SMAD proteins regulated by the recep-
tor) or a protein of another pathway, i.e. chap-
erone one (ShcA), bind to the activated TGFR-II 
receptor.
A type III receptor with a molecular mass of 
280−330kDa, enhances the ligand’s access to type 
I and type II receptors [2]. 
TGF-b pathway depends on SMAD proteins. 
SMAD2 and SMAD3 form complexes with TG-
FR-II and activin receptors (ActR). SMAD 1, 5 and 
8 are recognized by the bone morphogenetic pro-
tein receptor (BMPR) [52]. R-SMAD proteins bind 
to a mutual comediator SMAD4, binding both 
signal transmission pathways by TGFR and BMPR 
receptors. SMAD6 and 7 play a role of inhibitors 
of the following interactions: 1) TGFR-II-R-SMAD 
and 2) R-SMAD-Co-SMAD. Interaction between 
the kinase domain of the TGFR-II receptor and 
the conservative region of the C-terminal SMAD 
protein (MH2 domain) is highly specific [53].
The active TGFR-II receptor stimulates 
R-SMAD 2 or 3 protein phosphorylation within 
the serine residues in the conservative SS(M/V)
S motif in the C-terminal region. R-SMAD 2 and 
3 are bound to the endosomal protein, SMAD 
anchor for receptor activation (SARA). A het-
erodimer of the R-SMAD phosphorylated protein 
with the Co-SMAD protein is formed. Next, this 
complex is transported into the cell nucleus, how-
ever the mechanism of this nucleo-cytoplasmic 
transport has not been completely elucidated 
to date. This complex binds through the MH1 












Regulation of gene transcription
Translocation into the cell nucleus.






1, 2, 3, 5, 8 in the 
competition mechanism 
Interaction with 
Co-Smad and sending 
the complex 
for degradation 
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domain in the cell nucleus to CAGAC sequences 
(SMAD-binding domain — SBD) or with GC rich 
sequences in numerous gene promoter regions 
[54]. SMAD proteins interact with complexes re-
modelling chromatin (SWI/SNF) and with a DNA 
demethylating protein complex (DNA demethy-
lase — DNDM) [55]. Moreover, SMAD proteins 
exert impact on regulation of gene transcription 
in the cell nucleus: they induce the transcription 
through the activation of histone acetyltrans-
ferases (HAT) p300, CBP, GCN5 or inhibit gene 
transcription through the recruitment of histone 
deacetylases (HDAC), e.g. RBL1 [56].
Free SMAD proteins are characterized by 
low specificity to bind to DNA, therefore they 
must interact with each other and with factors 
being able to bind to DNA. Selective activity of 
SMAD proteins is owed to the interaction with 
transcriptive factors such as AP-1, ETS, C/EBPb, 
FoxH1 and FoxO [57].
Signal transmission along the SMAD path-
way may be modified at each level due to phos-
phorylation, ubiquitylation or ADP-ribosylation 
[58]. The way of enzymatic inhibition of SMAD 
activity in the cell nucleus is the following, as 
shown on Figure 2.
Inhibition of SMAD activity may be also 
achieved by inhibitory proteins SMAD7, which 
induce degradation of the TGFR-II receptor, 
inhibit R-SMAD phosphorylation and form 
a R-SMAD-Co-SMAD complex. I-SMAD proteins 
competing with R-SMAD for binding to the re-
ceptor or SMAD4 prevent signal transmission by 
TGF-b [59]. Furthermore, SMAD7 is also involved 
in the recruitment of SMURF2 ubiquitin ligase 
to TGF-b receptors, which leads to proteolytic 
and lysosomal degradation of TGFR-II-TGFR-II 
complexes, and Smad7 and Smad2 [60].
Factors inhibiting SMAD include core-
pressors, such as nuclear oncoproteins, c-SKI 
and c-SNO, which prevent formation of active 
R-SMAD-Co-SMAD complexes [61].
Completion of the process of signal transmis-
sion takes place through dephosphorylation of 
active R-SMAD proteins with the involvement of 
a specific phosphatase and through their ubiquiti-
nation and degradation in proteasome with copar-
ticipation of SMAD7. SMADs are thought to be 
also involved in the control of the expression of 
CDKN2B gene encoding p15, and CDKN1A gene 
encoding p21, c-myc, ID1 and ATF3 [62].
Part of proteins involved in DNA binding 
to SMADs is tissue specific. In respiratory dise-
ases, blocking of the inhibitor of DNA-binding 
1 (ID-1) expression in epithelial cells through 
formation of a complex with a corepressor of 
transcriptional activation factor 3 (ATF-3) seems 
to be significant [63].
Binding to various DNA-binding cofactors 
and involvement in numerous signalling path-
ways influence the SMAD-binding to gene pro-
moter regions, which have an impact on diversity 
of transcription responses in respective cells.
The main TGF-b-mediated signal transmis-
sion occurs with the involvement of SMADs. 
However, there are alternative pathways, in which 
the involvement of mitogen activated protein 
kinases (MAPK): JUN N-terminal kinase (JNK), 
extracellular signal-regulated kinases (ERK1 
and ERK2), p38 and phosphoinositide-3-kinase 
(PI3K).is postulated. Moreover, the TGF-b effect 
on signalling of the transcription nuclear factor 
kappa B (NF-kB) has been shown. The main NF-kB 
activity is anti-apoptotic [64]. SMAD-indepen-
dent pathway may be also activated by endoglins, 
beta-glucans, as well as an unspecified protein 
with phosphatidylinositol bindings showing 
coreceptor features. 
Regulation of gene transcription
Regulation of TGF-b gene transcription starts 
from the SMAD MH2 domain binding to a heterol-
ogous DNA-binding domain, e.g. Gal4p. It signal-
izes readiness of R-SMAD-Co-SMAD complexes 
to activate the transcription. SMAD proteins 
are involved in determining which genes will 
be activated in response to the TGF-b stimula-
tion. Particular molecules of the R-SMAD and 
Co-SMAD complex are able to bind to the DNA 
thread through the MH1 domain. The most pref-
erable is the binding to the palindromic sequence 
GTCTAGAC, although to initiate the process, the 
Figure 2. Modifications of signal transmission along SMAD pathway
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Table 2. SMADs interact with DNA-binding cofactors to specify TGF-b gene responses
Ligand Receptor II Receptor I SMAD Co-factor Target GEN Response






Mesoderm differentiation via Nodal in Xenopus 




ActR-I TFE3 PAI−1 Activation of platelet activating factor and pla-


















CBFA1 Osteocalcin? Osteoblast differentiation via BMP
BMP7 BMPR-IB
GDF5 ALK2 Others Others Mesoderm and endoderm induction and diffe-
rentiation in Drosophila? ? ALK1
ActR — activin receptor; ALK — anaplastic lymphoma kinase; AP-1 — activator protein 1; ATF-2 — activating transcription factor 2; BMP — bone morphogenetic 
protein; BMPR — bone morphogenetic protein receptor; CBFA — core-binding factor A; CREB — cyclic AMP-regulated enhancer-binding protein; FAST — forkhead 
activin signal transducer; IgA — immunoglobulin type A; GDF — growth differentation factor; LEF1 — lymphoid enhancer-binding factor 1; Nodal-lefty — nodal left-right 
determination factors; PAI-1 — plasminogen activator inhibitor-1; SAC — Staphylococcus aureus Cowan; SMAD — mothers against decapentaplegic, homolog of; 
TFE3 — transcription factor binding to immunoglobulin heavy constant mu enhancer 3
binding to AGAC is sufficient. These sites are 
called Smad-binding elements (SBE) [52]. They 
are frequently identified in respective regions for 
TGF-b genes, activins, and BMP. In a few genes, 
the ability to react to signals requires the presence 
of at least one SBE. However, it is not necessary 
for each SMAD subunit to be bound to DNA. 
The GTCTAGAC sequence, present within 
SBE, occurs on average once per 1024 pairs of 
bases in the genome or there is one such place 
in the regulated region of each gene of a moder-
ate size [65]. Three mechanisms of transcription 
regulation have been described in the literature:
1)  binding of the active R-SMAD-Co-SMAD 
complex to the transcription factor and next 
the binding of this multifactorial complex to 
the recognized DNA sequence;
2)  separate binding of SMAD and cofactor to 
DNA, next the interaction of these proteins 
and stabilization of enhanced properties;
3)  separate binding of SMAD and an additional 
factor to a definite DNA site — separate but 
synergistic activity. 
SMAD proteins combined with respective 
DNA receptors and cofactors form specific com-
plexes with a high affinity to DNA. These com-
plexes determine which target genes undergo 
transcription and to which response pathway 
they will be directed. SMAD proteins constitute 
the link of signalling pathways for the following 
molecules: transforming growth factor b (TGF-b), 
activins, Nodal proteins, bone morphogenetic 
proteins (BMP2, 7), and growth differentiation 
factor (GDF5) [66].
The most strongly activated gene in the TGF-b 
transcriptome is PAI-1 gene, whose main activa-
tor is at the same time the transforming growth 
factor TGF-b. Physiologically, phenomena of cell 
migration and remodelling of the extracellular 
matrix described for the plasminogen activator 
inhibitor (PAI-1) depend on TGF-b activity. In 
pathological processes, an elevated TGF-b lev-
el positively correlates with an increase in the 
PAI-1 inhibitor level. The extracellular matrix 
(ECM) is made up of collagens, glycoproteins, 
proteoglycans and glycosaminoglycans. ECM, to 
properly play its function, must be continuously 
remodelled, with the involvement of PAI-1 and 
PAI-2 factors as well as a thrombin activatable 
fibrinolysis inhibitor (TAFI) [67]. In to date 
studies, an increase in the PAI-1 serum level and 
TAFI activity has been stated in patients with 
mild and moderate asthma, who have not been 
treated before [68]. Current studies indicate an 
elevated PAI-1 serum level in patients with aller-
gic asthma after the challenge with a particular 
allergen (most frequently home dust mites), as 
compared to healthy subjects. A higher PAI-1 
level positively correlated with a degree of hy-
per-responsiveness [69]. Activation of the plasma 
coagulation cascade is associated with activation 
of blood platelets. Inflammation of bronchial 
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mucosa in asthma causes an enhanced inflow of 
activated mast cells, eosinophils, T lymphocytes, 
and blood platelets [70]. On the thrombocyte sur-
face, there are receptors of high and low affinity 
for IgE — the main immunoglobulin involved in 
the inflammatory reaction in asthma. It has been 
found that in patients with asthma, the number 
of IgE-binding platelets increases up to 50% 
in comparison with healthy subjects. After the 
provocation with specific allergens, a few-fold 
increase in blood platelet accumulation in bron-
chial vessels is observed [71]. Experimental stud-
ies on mice indicated the involvement of blood 
platelets, both in an initial and in a later phase of 
immediate hypersensitive reaction. This implies 
that blood platelets may also actively participate 
in the process of inflammation and remodelling 
in humans. A greater number of reticular plate-
lets has been found in the group of patients with 
allergic asthma as compared to healthy subjects, 
which demonstrates increased megakaryocytopoi-
esis [72]. Platelets are a source of inflammatory 
mediators, such as platelet factor (PF-4), regulated 
on activation normal t-cell expressed and secret-
ed cytokine (RANTES), platelet-derived growth 
factor (PDGF), main basic protein (MBP), plate-
let-activating factor (PAF), and P-selectin [73]. 
The presented data may suggest a significant role 
of blood platelets in the development of allergy 
and asthma, however further detailed studies are 
required in this subject [74, 75].
During the immune response in the mature 
plasma cell, the change in the class of synthesized 
antibodies takes place, which enables the produc-
tion of various classes and subclasses of immuno-
globulins, maintaining the same specificity. This 
phenomenon is possible due to the recombination 
between switch regions, which are found in an in-
tron, above exons for stable domains of the immu-
noglobulin molecule heavy chain. IgA molecule 
synthesis usually occurs as a result of switching 
from IgM. The change in synthesized isotope de 
novo is also possible. This causes a transcription 
of the gene for the heavy-chain constant region, 
whose expression is to be altered. The site of 
the transcription initiation is in “exon I” above 
each S region. Sµ/Sa fragments are formed in 
the process of recombination determining the 
change in synthesized antibody classes towards 
IgA [76]. TGF-b1 is a key mediator within the IgA 
subclass. It induces the transcription of Ca1 and 
Ca2 genes in B lymphocytes. TGF-b1 inhibits the 
expression of remaining isotopes, while TGF-b1 
induces the expression of Ia1-Ca1 transcripts. 
The whole process can be enhanced through the 
stimulation with the independent mitogen, Staph-
ylococcus aureus Cowan 1 (SAC). The Ia2-Ca2 
segment does not require additional stimulators 
of B lymphocytes and is transcribed only in the 
presence of TGF-b1 [77]. The conducted studies 
have revealed that in subjects with isolated deficit 
of IgA [78], a lowered number of Sµ/Sa fragments 
and a decreased mRNA expression for Ia-Ca are 
observed in the examination of peripheral blood 
mononuclear cells (PBMC). This implies the pres-
ence of a defect at the level of class switching in 
patients with deficiency of this immunoglobulin. 
Moreover, a reduced TGF-b1 level is found in 
serum of these patients. This suggests that the 
impaired synthesis of this cytokine, its defective 
activation, abnormal transmission by the SMAD 
system and in consequence an improper expres-
sion of the TGFR receptor on target cells may have 
an effect on formation of selective IgA deficit as 
well as other diseases based on deficiency of this 
immunoglobulin [77]. Selective IgA deficiency 
(sIgAD) is one of the factors worsening prognosis 
in asthma. Co-occurrence of both diseases has 
been observed in a certain group of patients. In 
patients with a positive history of asthma, an 
increased frequency of the diagnosis of selective 
IgA deficit and common variable immunodefi-
ciency (CVID) has been noted [79]. Due to some 
difficulties in defining the precise time of the 
disease onset and asymptomatic development 
of IgA deficit, it was not possible to determine 
which impairment is the first one to occur [80]. 
IgA deficits, with the presence of an elevated or 
stable IgE level, are commonly detected in al-
lergic diseases and bronchial asthma. There are 
some studies that indicated a decrease in the IgA 
level in serum of patients with bronchial hyper- 
-responsiveness and evident atopy in skin prick 
tests (SPT). It was also observed that the level of 
immunoglobulins negatively correlated with the 
intensity of symptoms in asthma patients. The 
following immunoglobulin profile is most often 
encountered: ↑IgE, IgM stable, IgA stable or ↓, 
IgG stable or↓IgG2. Although the constitutive 
levels of both immunoglobulins, IgA and IgG, are 
usually below normal range, only the IgA level 
correlates with severity of disease symptoms — 
the lower the level the more severe symptoms are 
[81]. Apart from susceptibility to atopy, frequent 
infections are one of the factors exacerbating the 
course of asthma and enhancing inflammatory 
reactions in the respiratory tract. In an antiviral 
response, a key role is played by Th2 lympho-
cytes whose function is among others to secrete 
Il-6 stimulating IgA production on the surface 
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of bronchial and alimentary tract mucosa. IgA 
deficit, an impaired expression, synthesis, and in-
duction of this immunoglobulin cause a decrease 
in efficiency of the immune system related to the 
mucosa−associated lymphoid tissues (MALT). 
A more severe course of infection leads to ex-
acerbation of the primary disease and its worse 
control. Similar values were observed in children 
with an elevated level of IgA, independent from 
IgE, in the study evaluating the prevalence of 
infections in a paediatric population. The conclu-
sion was drawn that the deficit of this immuno-
globulin is more important in the occurrence of 
recurrent infections in children than atopy [82]. 
The effect of TGF-b on the signalling pathway and 
switching of immunoglobulin classes can also 
influence the occurrence of IgA deficiency and 
cause more severe course of the disease, exacer-
bations, and worse asthma control.
The TGF-b factor activates the activating 
protein-1 transcription complex (APC) through 
the SMAD signalling pathway. There are three 
families of transcription proteins within this 
complex — the family of Fos proteins (c-Fos, 
FosB, Fra1, Fra2), Jun proteins (c-Jun, JunB, JunD) 
and activating transcription factors (ATFa, ATF2, 
ATF3, ATF4 and B-ATF) [83]. Jun and Fos proteins 
form complexes which play a key role in inducing 
inflammation in asthma. Jun/Jun homodimers are 
less stable and less capable of binding to DNA. 
Fos/Jun heterodimers are more stable complexes 
characterized by a higher affinity for DNA [84]. 
The Jun/Fos complex activates and regulates genes 
subject to overexpression in asthma, especially 
severe asthma. Active AP-1 directly reacts to the 
glucocorticoid receptor, which has a great im-
pact on asthma control and its steroid-resistant 
form. Conducted observations have proven an 
increase in activity of AP-1 transcription complex 
in the respiratory mucosa after the exposition to 
PMA (forbol ester, capable of activating protein 
kinase C), tumour necrosis factor a (TNF-a) and 
IL-1b interleukin as well as in the peripheral 
blood mononuclear cells after PMA stimulation. 
Further observations indicated an increase in 
the expression of c-fos and c-jun transcription 
factors resulting in an elevated level of c-Fos and 
c-Jun proteins, being the product of these genes 
activation [85]. Moreover, an increase in the ac-
tivity of c-Jun N-terminal kinases leading to the 
enhancement of the cell response to proinflamma-
tory cytokines was also noted. In the respiratory 
tract of asthma patients, a constitutive increase 
in the c-Fos expression was found [86]. An ac-
tive complex AP-1 is necessary to differentiate 
native T lymphocytes to Th1 and Th2 fraction, 
which play a special role in the T-cell dependent 
immune response. Th2 lymphocytes, affected by 
AP-1, secrete proinflammatory factors such as IL-
4, IL-5 and IL-15. Moreover, the AP-1 transcription 
complex activated by TGF-b activates genes of 
the matrix metalloproteinase (MMP)-1, MMP-3, 
and MMP-9 inducing the matrix decomposition 
and remodelling. Transcription of proinflamma-
tory cytokines, such as IL-1 and IL-2 as well as 
iterferon gamma (IFN-g), is activated through the 
AP-1 factor and suppressed by the glucocorticoid 
receptor (GR) [87]. Repression of the proinflam-
matory gene activity by glucocorticosteroids is 
possible due to vicinity of the glucocorticoid re-
sponse element (GRE) and the AP-1 transcription 
factor adjacent to the DNA promoter region. Then 
the GR receptor interacts with the c-Jun protein, 
which directly leads to the repression of genes 
[88]. Another way of inhibiting the gene expres-
sion by the GR receptor is the so called cross-
talk mechanism (i.e. protein-protein interaction) 
depending on the interaction with transcription 
factors, such as NFkB, AP-1, NFAT, or STAT 
[89]. Indirect interaction through transcription 
proteins is the main mechanism regulating the 
immune response through glucocorticosteroids. 
They bind to the GR receptor and act as an an-
ti-inflammatory agent reducing AP-1 production 
and increasing the NFkB inhibitory protein (IkBa 
— nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor). In asthma patients, 
an increased constitutive level of the AP-1 tran-
scription factor is observed [90]. This causes 
binding of the AP-1 complex to the GR receptor, 
preventing glucocorticosteroids from binding to 
the glucocorticoid response element (GRE) and 
from inhibiting the AP-1 synthesis. This has been 
evidenced in the study on two groups of patients 
who were either corticosteroid-sensitive or -resis-
tant. In the latter group, a few-fold higher level of 
the proinflammatory c-fos AP-1 unit was detected 
as compared to patients sensitive to treatment 
with inhaled and/or systemic steroids. A similar 
phenomenon of steroid-resistance is observed in 
such pathological states as rheumatoid arthritis, 
leukemia, and graft rejection [91].
Tgf-smad signalling pathway in selected 
pulmonary diseases
Transforming Growth factor b is also involved 
in fibrosis and airway remodelling in chronic 
obstructive pulmonary disease (COPD) [92]. The 
TGFb level in primary cells, epithelial cells, ma-
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crophages, fibroblasts isolated from COPD-lungs 
has increased, that may suggest an impact of 
TGFb signalling has an impact on the proccess 
of progression of COPD [93]. In addition, several 
studies have reported elevated TGF-b1 expression 
in the airway epithelium in patients with COPD 
or chronic bronchitis, as well as smokers [21]. 
The TGF-b signalling pathway may also be 
involved is idiopathic pulmonary fibrosis (IFP), 
in which a crucial role is played by epithelial-
mesenchymal transition (EMT) [94]. EMT is 
a process whereby differentiated epithelial cells 
transform into mesenchymal phenotype, which 
can then differentiate into fibroblasts and myofi-
broblasts [95]. TGF-b is a hard inductor of fibro-
genesis, as well as a major mediator of EMT via 
SMAD-dependent pathway [96, 97]. 
Furthermore, TGF-SMAD molecular pathway 
is involved in pathogenesis of primary pulmonary 
hypertension (PPH) [98, 99]. Some studies indi-
cate, that pulmonary artery smooth muscle cells 
(PASMCs) from patients with PPH exhibit ab-
normal growth responses to TGF-b superfamily 
members [100]. It is postulated that BMPR2 
mutation may disrupt the entire TGF-SMAD 
signalling pathway, resulting in hypertrophy 
and hyperplasia of vascular smooth muscle and 
endothelial cells [101]. 
Summary
A TGF-b factor is evidently one of the main 
cytokines involved in mediating inflammation and 
remodelling processes in bronchial airways [1]. 
The main pathway of signal transmission via TGF-b 
occurs with the interaction of the SMAD proteins. 
The knowledge of the transmission pathway and 
the processes of gene transcription determining 
variety of response induced by this cytokine allows 
clinicians to evaluate immune reactions in patients.
Further cognitive and practical studies may 
form the basis for creation of specific biological 
therapy. Designing peptide and protein inhibitors 
of the TGF-b receptor, selective for TGF-b1, may in 
future offer hope for patients with severe asthma.
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